TY - JOUR
T1 - Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL Study Group in Japan
AU - Shimada, Kazuyuki
AU - Matsue, Kosei
AU - Yamamoto, Kazuhito
AU - Murase, Takuhei
AU - Ichikawa, Naoaki
AU - Okamoto, Masataka
AU - Niitsu, Nozomi
AU - Kosugi, Hiroshi
AU - Tsukamoto, Norifumi
AU - Miwa, Hiroshi
AU - Asaoku, Hideki
AU - Kikuchi, Ako
AU - Matsumoto, Morio
AU - Saburi, Yoshio
AU - Masaki, Yasufumi
AU - Yamaguchi, Motoko
AU - Nakamura, Shigeo
AU - Naoe, Tomoki
AU - Kinoshita, Tomohiro
PY - 2008
Y1 - 2008
N2 - Purpose: To evaluate the safety and efficacy of rituximab-containing chemotherapies for intravascular large B-cell lymphoma (IVLBCL). Patients and Methods: We retrospectively analyzed 106 patients (59 men, 47 women) with IVLBCL who received chemotherapy either with rituximab (R-chemotherapy, n = 49) or without rituximab (chemotherapy, n = 57) between 1994 and 2007 in Japan. The median patient age was 67 years (range, 34 to 84 years). The International Prognostic Index was high-intermediate/high in 97% of patients. Results: The complete response rate was higher for patients in the R-chemotherapy group (82%) than for those in the chemotherapy group (51%; P = .001). The median duration of follow-up for surviving patients was 18 months (range, 1 to 95 months). Progression-free survival (PFS) and overall survival (OS) rates at 2 years after diagnosis were significantly higher for patients in the R-chemotherapy group (PFS, 56%; OS, 66%) than for patients in the chemotherapy group (PFS, 27% with P = .001; OS, 46% with P = 0.01). Multivariate analysis revealed that the use of rituximab was favorably associated with PFS (hazard ratio [HR], 0.45; 95% CI, 0.25 to 0.80; P = .006) and OS (HR, 0.42; 95% CI, 0.21 to 0.85; P = .016). Treatment-related death was observed in three patients (6%) who received R-chemotherapy and in five patients (9%) who received chemotherapy. Conclusion: Our data suggest improved clinical outcomes for patients with IVLBCL in the rituximab era. Future prospective studies of rituximab-containing chemotherapies are warranted.
AB - Purpose: To evaluate the safety and efficacy of rituximab-containing chemotherapies for intravascular large B-cell lymphoma (IVLBCL). Patients and Methods: We retrospectively analyzed 106 patients (59 men, 47 women) with IVLBCL who received chemotherapy either with rituximab (R-chemotherapy, n = 49) or without rituximab (chemotherapy, n = 57) between 1994 and 2007 in Japan. The median patient age was 67 years (range, 34 to 84 years). The International Prognostic Index was high-intermediate/high in 97% of patients. Results: The complete response rate was higher for patients in the R-chemotherapy group (82%) than for those in the chemotherapy group (51%; P = .001). The median duration of follow-up for surviving patients was 18 months (range, 1 to 95 months). Progression-free survival (PFS) and overall survival (OS) rates at 2 years after diagnosis were significantly higher for patients in the R-chemotherapy group (PFS, 56%; OS, 66%) than for patients in the chemotherapy group (PFS, 27% with P = .001; OS, 46% with P = 0.01). Multivariate analysis revealed that the use of rituximab was favorably associated with PFS (hazard ratio [HR], 0.45; 95% CI, 0.25 to 0.80; P = .006) and OS (HR, 0.42; 95% CI, 0.21 to 0.85; P = .016). Treatment-related death was observed in three patients (6%) who received R-chemotherapy and in five patients (9%) who received chemotherapy. Conclusion: Our data suggest improved clinical outcomes for patients with IVLBCL in the rituximab era. Future prospective studies of rituximab-containing chemotherapies are warranted.
UR - http://www.scopus.com/inward/record.url?scp=49249136514&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=49249136514&partnerID=8YFLogxK
U2 - 10.1200/JCO.2007.15.4278
DO - 10.1200/JCO.2007.15.4278
M3 - Article
C2 - 18506023
AN - SCOPUS:49249136514
SN - 0732-183X
VL - 26
SP - 3189
EP - 3195
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 19
ER -